ACADIA Operating Cycle from 2010 to 2026

ACAD Stock  USD 23.99  0.34  1.40%   
ACADIA Pharmaceuticals' Operating Cycle is decreasing over the years with slightly volatile fluctuation. Operating Cycle is expected to dwindle to 150.53. During the period from 2010 to 2026 ACADIA Pharmaceuticals Operating Cycle annual values regression line had geometric mean of  562.60 and mean square error of 4.4 M. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
158.46
Current Value
150.53
Quarterly Volatility
2.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 589.8 M or Total Revenue of 1.2 B, as well as many indicators such as Price To Sales Ratio of 2.71, Dividend Yield of 0.0 or PTB Ratio of 4.46. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ACADIA Stock
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
Analyzing ACADIA Pharmaceuticals's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing ACADIA Pharmaceuticals's current valuation and future prospects.

Latest ACADIA Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of ACADIA Pharmaceuticals over the last few years. It is ACADIA Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ACADIA Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

ACADIA Operating Cycle Regression Statistics

Arithmetic Mean1,584
Geometric Mean562.60
Coefficient Of Variation155.53
Mean Deviation1,760
Median282.77
Standard Deviation2,463
Sample Variance6.1M
Range9.7K
R-Value(0.56)
Mean Square Error4.4M
R-Squared0.31
Significance0.02
Slope(273.09)
Total Sum of Squares97.1M

ACADIA Operating Cycle History

2026 150.53
2025 158.46
2024 137.79
2023 337.31
2022 282.77
2021 199.55
2020 213.51

About ACADIA Pharmaceuticals Financial Statements

ACADIA Pharmaceuticals stakeholders use historical fundamental indicators, such as ACADIA Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in ACADIA Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on ACADIA Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 158.46  150.53 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.128
Earnings Share
1.55
Revenue Per Share
6.251
Quarterly Revenue Growth
0.113
Return On Assets
0.0511
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.